JP2015503623A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503623A5
JP2015503623A5 JP2014552325A JP2014552325A JP2015503623A5 JP 2015503623 A5 JP2015503623 A5 JP 2015503623A5 JP 2014552325 A JP2014552325 A JP 2014552325A JP 2014552325 A JP2014552325 A JP 2014552325A JP 2015503623 A5 JP2015503623 A5 JP 2015503623A5
Authority
JP
Japan
Prior art keywords
formulation
romidepsin
amount
etoh
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503623A (ja
JP6170946B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021212 external-priority patent/WO2013106696A1/en
Publication of JP2015503623A publication Critical patent/JP2015503623A/ja
Publication of JP2015503623A5 publication Critical patent/JP2015503623A5/ja
Application granted granted Critical
Publication of JP6170946B2 publication Critical patent/JP6170946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552325A 2012-01-12 2013-01-11 ロミデプシン製剤及びその使用 Active JP6170946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586066P 2012-01-12 2012-01-12
US61/586,066 2012-01-12
PCT/US2013/021212 WO2013106696A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2015503623A JP2015503623A (ja) 2015-02-02
JP2015503623A5 true JP2015503623A5 (enExample) 2016-03-03
JP6170946B2 JP6170946B2 (ja) 2017-07-26

Family

ID=47604232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552325A Active JP6170946B2 (ja) 2012-01-12 2013-01-11 ロミデプシン製剤及びその使用

Country Status (8)

Country Link
US (3) US20130184225A1 (enExample)
EP (1) EP2802340B1 (enExample)
JP (1) JP6170946B2 (enExample)
CN (1) CN104168908A (enExample)
AU (1) AU2013201937B8 (enExample)
CA (1) CA2863291A1 (enExample)
MX (1) MX2014008390A (enExample)
WO (1) WO2013106696A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630311A (en) * 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106137980B (zh) * 2015-03-31 2021-04-13 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US20210169871A1 (en) * 2018-04-05 2021-06-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
JP2010105965A (ja) * 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途

Similar Documents

Publication Publication Date Title
HRP20210212T1 (hr) Triciklični spoj kao antikancerogeni agensi
JP2015078230A5 (enExample)
JP2013014622A5 (enExample)
JP2015502926A5 (enExample)
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
JP2014533667A5 (enExample)
BR112015016002A2 (pt) compostos, composições farmacêuticas, complexos químicos e respectivos usos e método para tratar ou prevenir infecção bacteriana
JP2016510019A5 (enExample)
BR112012026289A2 (pt) composto orgânico para uso no tratamento de câncer do fígado
JP2012502037A5 (enExample)
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
JP2011105738A5 (enExample)
JP2015508103A5 (enExample)
EA201591686A1 (ru) Пиридинильные и конденсированные пиридинильные производные триазолона
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2017513917A5 (enExample)
JP2014525449A5 (enExample)
JP2014531401A5 (enExample)
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
ES2598753T3 (es) Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada